References
- Pardanani A, Akin C, Valent P. Pathogenesis, clinical features, and treatment advances in mastocytosis. Best Pract Res Clin Haematol 2006;19:595–615.
- Brown PS, Jr., Parenteau GL, Dirbas FM, et al Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival. Proc Natl Acad Sci USA 1991;88:2663–2667.
- Sotlar K, Horny HP, Simonitsch I, et al CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens. Am J Surg Pathol 2004;28:1319–1325.
- Vega-Ruiz A, Cortes JE, Sever M, et al Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leuk Res 2009;33:1481–1484.
- Quintas-Cardama A, Kantarjian H, Verstovsek S. Treatment of systemic mastocytosis with denileukin diftitox. Am J Hematol 2007;82:1124.
- Quintas-Cardama A, Aribi A, Cortes J, Giles FJ, Kantarjian H, Verstovsek S. Novel approaches in the treatment of systemic mastocytosis. Cancer 2006;107:1429–1439.